Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.82 |
| ▸ | ATRIP | Q8WXE1 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501448 | 0.90 | ATR (1.00) | ATRATRIP | |
| SCHEMBL30140462 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL20081925 | 0.88 | ATR (0.82) | ATRATRIP | |
| SCHEMBL17501418 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501192 | 0.88 | ATR (0.82) | ATRATRIP | |
| SCHEMBL17527663 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501625 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL20081829 | 0.88 | ATR (0.82) | ATRATRIP | |
| SCHEMBL18109985 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL18109965 | 0.86 | ATR (1.00) | ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661560-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025440-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| WO-2018153969-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| WO-2018153971-A1 | COMBINATION OF ATR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| WO-2018153972-A1 | COMBINATION OF ATR KINASE INHIBITORS AND ANTIANDROGENS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| EP-3661560-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025440-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2018153973-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153972-A1 | COMBINATION OF ATR KINASE INHIBITORS AND ANTIANDROGENS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153969-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153971-A1 | COMBINATION OF ATR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |